This year the CDISC Glossary update included a more robust and frequently used request process for new terms because the Glossary activity was better integrated into the CDISC Controlled Terminology Team that supports the exchange of digital information. The Glossary seeks to eliminate semantic confusion in human information exchange and disambiguate the meaning of terms, acronyms, abbreviations, and initials used in the various foundational standards developed by CDISC for clinical research. The Glossary also serves as an educational resource for the clinical research community, by defining relevant terms pertaining to clinical research, including eClinical investigations, sponsored by the pharmaceutical industry or a federal agency. The team updated about 50 existing terms; reviewed close to 100 new terms that had been proposed; and updated or added more than 150 Acronyms/Abbreviations/Initials not included last year. In addition, sources for definitions from new guidelines are provided in the Glossary.xls format as a tab for ease of use.
Download Statistics for the Glossary publication files from the NCI FTP site from public review month to November
To complete the 2018 expansion of the published 2017 CDISC Glossary, the team met every week virtually; held a two-day face-to-face workshop of intensive team review and preparation of related-term clusters that would be useful to a user to consider as a group; and prepared the Glossary for annual public review in September. Terms that fit the new concept of definition “clusters” were monitoring, exposure, study participant/subject, investigator, just to give a few examples.
All formats of the updated Glossary, the Glossary directory, the New Term request form are available at:
https://www.cancer.gov/research/resources/terminology/cdisc
CDISC Glossary Team members are:
Helle Gawrylewski as Lead, Guido Claes, and Denise Adelman (all Janssen R&D of J&J); Erin Muhlbradt (EVS in NCI/NIH); Art Gertel (MedSciCom); Stephen Raymond (ERT); Jon Hilton (F. Hoffmann-La Roche Ltd); Chris Gemma (CDISC); and Melissa Cook (MC Consulting).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.